A widely used over-the-counter supplement, frequently turned to by millions of older adults to manage joint pain and support mobility, has been linked to a potentially concerning outcome in individuals already struggling with early cognitive impairment. Researchers at the University of Florida have uncovered evidence suggesting that the use of glucosamine is associated with a greater likelihood that mild cognitive impairment (MCI) will progress into full-blown dementia.
The findings, recently published in the journal Nature Metabolism, provide a sobering look at how common lifestyle choices might interact with neurodegenerative conditions. Mild cognitive impairment is a clinical stage characterized by measurable deficits in memory, language, or executive function that exceed what is expected during normal aging. While these individuals often remain functional in their daily lives, the transition from MCI to dementia represents a critical and often devastating clinical milestone.
A Popular Supplement Comes Under Scrutiny
The implications of this research are vast, given the sheer number of people living with neurodegenerative disorders. "In the United States, there are about 7 million people living with Alzheimer’s and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of the University of Florida’s McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."
Glucosamine is a naturally occurring, sugar-related molecule that is synthesized into a popular dietary supplement. It is widely available without a prescription and is a staple in the medicine cabinets of the aging population, primarily marketed to alleviate joint discomfort and promote structural joint health. Because of its ubiquity, researchers at the University of Florida sought to determine if its routine consumption might influence the trajectory of Alzheimer’s disease and related dementias (ADRD).
The research team, which included Dr. Yi Guo and Dr. Jiang Bian, employed sophisticated artificial intelligence to parse through deidentified health records from UF Health, spanning from 2012 to 2024. By focusing on a large cohort of patients already diagnosed with either ADRD or MCI, the team established a substantial dataset. Within these groups, approximately 8% of patients reported the regular use of glucosamine, representing nearly 1,900 individuals with ADRD and over 2,700 individuals with MCI.
Glucosamine Linked to Dementia Progression
After applying rigorous statistical adjustments to account for variables such as age, sex, and various demographic factors, the team discovered a statistically significant correlation. Glucosamine use was associated with a 25% higher likelihood that patients in the MCI category would progress to a formal diagnosis of dementia.
Furthermore, among the subset of patients who had already been diagnosed with ADRD, the use of glucosamine was linked to a 25% higher mortality risk, indicating a greater likelihood of death within a defined clinical period. Interestingly, this increased mortality association was not observed in the MCI group, a distinction that researchers suggest may imply that glucosamine’s detrimental effects become more pronounced once dementia is already firmly established in the brain.
While the data are provocative, the researchers emphasize that these findings represent an association, not definitive proof of causality. "The electronic health record data are very provocative," noted Matt Gentry, Ph.D., chair of the UF Department of Biochemistry and Molecular Biology and a co-author of the study. "While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."
Observational studies, by their nature, cannot rule out the possibility that other underlying differences between those who choose to take supplements and those who do not might be driving these results. Nevertheless, the strength of the signal within the patient records is enough to warrant deeper scientific inquiry.
A Metabolic Pathway May Help Explain the Link
Beyond the clinical data, the researchers sought to identify a biological mechanism that could explain why a joint supplement might exacerbate cognitive decline. Their investigation pointed toward a fundamental metabolic pathway: the process of attaching sugar structures to proteins.
In healthy cellular biology, this process—known as glycosylation—is essential. It allows proteins to fold correctly and function as the "molecular machines" that power cellular life. However, the research team found that this process appears to become dysregulated and excessively active in the context of Alzheimer’s disease. Sun suggested that this abnormal metabolic activity could eventually serve as a novel target for therapeutic intervention.
"Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles," Sun explained.
For decades, the mainstream scientific approach to Alzheimer’s has centered on the accumulation of amyloid-beta plaques between brain cells and the formation of twisted tau protein tangles inside neurons. While these remain the hallmark features of the disease, the scientific community is increasingly pivoting toward a broader understanding of neurodegeneration, one that incorporates metabolic dysfunction as a primary driver rather than a secondary symptom.
Mapping Thousands of Molecules in the Brain
To achieve this level of granular detail, the team utilized advanced spatial technology developed in Sun’s laboratory. This method allows scientists to visualize and map thousands of distinct molecules created during the metabolic process. By breaking down how the body processes food and drugs, the technology can uncover intricate biochemical pathways that have historically remained hidden from view.
The team focused their attention on how glucosamine interacts with the brain. Because glucosamine is a sugar-related molecule, it has the ability to cross the blood-brain barrier—the highly selective, protective membrane that keeps most substances in the bloodstream from entering the brain. Once it traverses this barrier, glucosamine enters the biochemical pathways that construct complex sugar structures, which are then attached to proteins.
The researchers hypothesize that the biological environment of the brain determines whether this process is beneficial or harmful. A brain already compromised by Alzheimer’s disease appears to possess a unique, perhaps heightened, vulnerability to this metabolic interference compared to a healthy brain.
Experimental Evidence: Mice and Human Tissue
To test the hypothesis that this metabolic overactivity contributes directly to cognitive decline, the researchers turned to genetically modified mouse models. When these mice were treated with glucosamine, the team observed a significant increase in the attachment of sugar residues to proteins within brain cells. Concurrently, the treated mice exhibited worsened deficits in social memory—the ability to recognize other animals—compared to the control group.
In a crucial follow-up, the researchers used a chemical treatment to suppress the sugar-tagging process in the mice. When this pathway was inhibited, the animals’ memory performance improved. This suggests that the excessive sugar tagging is not merely a bystander to the disease, but may play a functional role in the memory impairment observed.
Finally, the team collaborated with Stefan Prokop, M.D., to examine human brain tissue samples provided by the UF Neuromedicine Brain and Tissue Bank. The specimens from individuals who had died with Alzheimer’s disease revealed a clear pattern: significantly higher levels of sugar attachment compared to brain tissue from healthy control subjects.
"What we found in Alzheimer’s is that this sugar-tagging system appears to be overactive," Gentry stated. "The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it."
These findings represent a significant shift in the narrative surrounding metabolic health and neurodegeneration. While the results raise critical questions regarding the use of glucosamine in patients with cognitive impairment, they do not yet serve as an official clinical mandate for patients to cease supplementation. The research team emphasizes that a controlled human clinical trial is the necessary next step to confirm these findings and to determine which specific patient populations are most at risk, providing the clinical certainty required for future medical guidelines.
